INS and type 2 diabetes mellitus: Numerous clinical trials have indicated that ACE inhibitors and angiotensin receptor blockers (ARBs) decrease the propensity to develop type 2 diabetes in high-risk patients,106–108 likely due to insulin sensitivity improvement.109